
Breast cancer mostly includes common types. But, a few rare forms are very challenging to diagnose and treat.
These rare cancers, like low-grade adenosquamous carcinoma (LGASC) and lipid-rich carcinoma, make up less than 0.1% of all cases. They are a big problem for doctors and hospitals.
At Liv Hospital, we know how important it is to understand these hard-to-find cancers. We aim to improve precision medicine and healthcare worldwide.
Key Takeaways
- Rare forms of breast cancer are diagnosed in less than 0.1% of cases.
- Examples include low-grade adenosquamous carcinoma (LGASC) and lipid-rich carcinoma.
- These cancers pose unique diagnostic and treatment challenges.
- Understanding rare breast cancers is key for better precision medicine.
- Liv Hospital is dedicated to top-notch care for patients from around the world.
The Landscape of Breast Cancer Prevalence

It’s key to grasp breast cancer prevalence to craft better health plans and treatments. This disease varies greatly, shaped by genetics, lifestyle, and where you live.
Global Breast Cancer Statistics
Breast cancer is a leading cancer worldwide, with big differences in who gets it. It hits millions of women, mostly in rich countries.
Some important stats on breast cancer globally are:
- More than 2 million new cases each year.
- Big gaps in who gets sick and who dies from it.
- Younger women in some places are getting it more often.
Distribution of Common vs. Rare Breast Cancer Types

The types of breast cancer vary a lot. Invasive ductal carcinoma is the most common, making up 70-80% of cases. But rare types, like Low Grade Adenosquamous Carcinoma (LGASC), are much rarer. This makes finding and treating them harder.
Understanding the differences between common and rare breast cancers is important for several reasons:
- Rare types are hard to diagnose because they look like harmless growths.
- Treatment plans for common and rare cancers are different.
- Knowing how common and rare cancers spread helps in research and health efforts.
Comprehensive Overview of Types of Breast Cancer
Breast cancer is a complex disease with many subtypes. Each subtype has its own characteristics. Understanding these differences is key to making accurate diagnoses and effective treatment plans.
Histological Classification Systems
Histological classification systems help categorize breast cancer into different types. They look at the microscopic appearance of tumor cells. The most common system is based on where the tumor starts in the breast, like ductal or lobular carcinoma.
According to the (SEER), knowing these subtypes is vital. It helps determine prognosis and treatment.
The histological classification includes:
- Ductal carcinoma in situ (DCIS)
- Invasive ductal carcinoma (IDC)
- Lobular carcinoma in situ (LCIS)
- Invasive lobular carcinoma (ILC)
Molecular Subtypes and Their Significance
Molecular subtyping of breast cancer is now key. It identifies specific genetic characteristics of the tumor. The main subtypes are Luminal A, Luminal B, HER2-positive, and Triple-negative breast cancer.
Each subtype has its own clinical implications. They respond differently to treatments.
|
Molecular Subtype |
Characteristics |
Treatment Response |
|---|---|---|
|
Luminal A |
ER+, PR+, HER2- |
Generally responsive to hormone therapy |
|
Luminal B |
ER+, PR+/-, HER2+/- |
Responsive to hormone therapy; may benefit from targeted therapy |
|
HER2-positive |
HER2+, ER+/- , PR+/- |
Responsive to HER2-targeted therapy |
|
Triple-negative |
ER-, PR-, HER2- |
Limited response to targeted therapies; often treated with chemotherapy |
Staging and Grading in Breast Neoplasms
Staging and grading are vital in evaluating breast cancer. Staging shows how far the tumor has spread. Grading looks at the tumor’s aggressiveness based on its microscopic appearance.
The TNM system is the most common staging system. It considers the tumor’s size (T), nearby lymph nodes (N), and metastasis (M).
Accurate staging and grading are key for prognosis and treatment decisions. Rare histologic subtypes often have unique genetic profiles. These can affect their staging and grading.
Common Breast Tumors and Their Characteristics
There are many types of breast tumors, each with its own traits. At Liv Hospital, we focus on treating different kinds of breast cancer. Our team knows that a detailed approach is key to managing these conditions well.
Invasive Ductal Carcinoma: The Most Common Type
Invasive ductal carcinoma (IDC) is the most common breast cancer, making up 70-80% of cases. It starts in the milk ducts and spreads to other breast tissue. If not treated early, it can spread to other parts of the body.
To diagnose IDC, doctors use mammograms and ultrasounds, followed by a biopsy. Treatment may include surgery, radiation, chemotherapy, or targeted therapy. This depends on the tumor’s size and how far it has spread.
Invasive Lobular Carcinoma: Features and Prevalence
Invasive lobular carcinoma (ILC) is the second most common, making up 10% of invasive cases. It starts in the lobules and can spread to other tissues. ILC is hard to find with just a mammogram, so other tests like ultrasound or MRI are needed.
Treatment for ILC is similar to IDC, with surgery being the main option. Whether to have a mastectomy or lumpectomy depends on the disease’s extent. Hormone therapy might also be suggested based on the tumor’s hormone receptors.
Other Frequently Diagnosed Breast Cancer Forms
There are other types of breast cancer too. These include:
- Tubular carcinoma: A rare form of IDC with a good outlook.
- Mucinous carcinoma: Known for its mucin content.
- Medullary carcinoma: A rare type with a unique look.
|
Type of Breast Cancer |
Prevalence |
Key Characteristics |
|---|---|---|
|
Invasive Ductal Carcinoma |
70-80% |
Originates in milk ducts, invades surrounding tissue |
|
Invasive Lobular Carcinoma |
10% |
Begins in lobules, can be difficult to detect |
|
Tubular Carcinoma |
Rare |
Favorable prognosis, subtype of IDC |
|
Mucinous Carcinoma |
Rare |
Characterized by mucin production |
Knowing about these common breast tumors is key to creating effective treatment plans. At Liv Hospital, we aim to provide care that meets each patient’s unique needs.
Defining Rarity in Breast Cancer Diagnosis
It’s important to know what makes a breast cancer rare. This knowledge helps doctors and patients understand treatment options better. Being called ‘rare’ affects how a cancer is treated and how well a patient does.
Statistical Thresholds for “Rare” Classification
The term ‘rare’ in medicine means something happens very little. For breast cancer, a type is rare if it’s less than 1% of all cases. Some say less than 0.1% is even more rare.
Some breast cancers are so rare, they make up less than 0.1% of all cases. These are the rarest types.
|
Rarity Classification |
Percentage of Total Breast Cancer Cases |
Examples of Breast Cancer Types |
|---|---|---|
|
Common |
>10% |
Invasive Ductal Carcinoma |
|
Uncommon |
1-10% |
Invasive Lobular Carcinoma |
|
Rare |
0.1-1% |
Lipid-Rich Carcinoma |
|
Extremely Rare |
Low Grade Adenosquamous Carcinoma (LGASC) |
Challenges in Identifying Uncommon Breast Carcinomas
Diagnosing rare breast cancers can be quite challenging. Doctors might not see these cases often. This makes it tough to diagnose and treat.
These cancers can look different or be hard to tell apart. This makes diagnosis even harder.
Addressing these challenges requires improved testing methods and expert consultations. We also need to be careful and think of rare cancers when they don’t look typical. This helps get the right treatment.
Low Grade Adenosquamous Carcinoma (LGASC): The World’s Rarest Breast Cancer
LGASC is the rarest breast cancer, with less than 150 cases worldwide. This rarity makes it a focus of interest in the medical field.
Extreme Rarity: Fewer Than 150 Documented Cases Worldwide
LGASC is rare and poses challenges in diagnosis and treatment. With so few cases, there’s limited data. This makes it hard for doctors to set standard treatments.
We have compiled a summary of the key statistics related to LGASC:
|
Characteristic |
Description |
|---|---|
|
Documented Cases Worldwide |
Fewer than 150 |
|
Classification |
Rare Breast Cancer Subtype |
|
Diagnostic Challenges |
Limited data, complex histological features |
Distinctive Histological Features of LGASC
LGASC has unique features that set it apart from other breast cancers. It has both glandular and squamous elements. This makes it hard to diagnose accurately.
Key Histological Features:
- Glandular and squamous differentiation
- Complex tumor architecture
- Low-grade malignant cells
Genetic Profile and Frequent PIK3CA Mutations
Studies have found that LGASC often has PIK3CA gene mutations. This knowledge helps us understand the tumor and develop targeted treatments.
There’s growing interest in how PIK3CA mutations affect LGASC. This could lead to more tailored treatments.
Clinical Presentation and Diagnostic Markers
LGASC can be hard to diagnose because its symptoms are not specific. Diagnostic markers and imaging are key to spotting this rare cancer.
Diagnostic Approaches:
- Imaging techniques (e.g., mammography, ultrasound)
- Histopathological examination
- Molecular testing for specific mutations
Lipid-Rich Carcinoma: An Exceptionally Rare Breast Tumor Type
Lipid-rich carcinoma is a rare and unique breast tumor. It presents challenges in diagnosis because of its special cellular makeup. This type of breast cancer is very rare, making it a focus for both diagnosis and research.
Unique Cellular Composition and Appearance
The lipid-rich carcinoma has cells full of intracellular lipid. This makes it look different under a microscope. This characteristic lipid-rich cytoplasm sets it apart from other breast cancers. The lipids in the cells can sometimes make it hard to tell it apart from benign conditions or other cancers.
The unique cells of lipid-rich carcinoma make diagnosis tricky. But they also show why we need advanced techniques to spot this rare tumor. The cells are big and have a clear or foamy look because of the high lipid content.
Diagnostic Criteria and Pathological Identification
To diagnose lipid-rich carcinoma, a detailed pathological exam is needed. This often includes immunohistochemical staining to check for specific markers. The criteria include a lot of cells with lipid-rich cytoplasm, over 90% of the tumor cells. Pathologists must be careful to tell it apart from other tumors that might look similar, like glycogen-rich or clear cell carcinomas.
Getting the diagnosis right is key for treating lipid-rich carcinoma properly. Advanced diagnostic methods, like molecular profiling, help tell this rare subtype apart from other breast cancers.
Documented Cases and Demographic Patterns
Lipid-rich carcinoma is one of the rarest breast cancers, with few documented cases. The rarity of this tumor makes it hard to find clear patterns or rates. But studies show it can happen in a wide age range, like other breast cancers. The rarity of lipid-rich carcinoma shows we need more research into its causes, diagnosis, and treatment.
Recording cases and studying demographic patterns are key to understanding lipid-rich carcinoma better. Working together, researchers and doctors can learn more about this rare breast cancer subtype.
Oncocytic Carcinoma: Rare Cellular Characteristics
Oncocytic carcinoma is a rare and interesting type of breast cancer. It is known for its unique cells, which are different from most breast cancers.
Mitochondrial Abnormalities and Cellular Features
This cancer is marked by cells full of mitochondria. Mitochondrial abnormalities play a big role in how it behaves. The cells are big and have a special look because of the many mitochondria.
Challenges in Accurate Diagnosis
It’s hard to diagnose oncocytic carcinoma because it’s so rare. Accurate diagnosis needs a close look at the cells. This often includes special tests to check for mitochondrial issues.
Global Incidence and Case Documentation
Oncocytic carcinoma is very rare, with only a few cases found around the world. Below is a table showing the few documented cases.
|
Year |
Number of Cases |
Source |
|---|---|---|
|
2010 |
5 |
Journal of Breast Cancer |
|
2015 |
3 |
International Journal of Cancer |
|
2020 |
2 |
Breast Cancer Research |
Rare breast cancers like oncocytic carcinoma have unique genes. Knowing these genes is key to creating new treatments.
Sebaceous Carcinoma of the Breast: Diagnostic Challenges
Sebaceous carcinoma of the breast is very rare and hard to diagnose. Its unique features make it a complex case for doctors.
Origin from Sebaceous Glands: A Unique Pathway
Sebaceous carcinoma starts in sebaceous glands, which are not common in the breast. This makes it different from usual breast cancers.
These glands are rare in the breast. When they turn into carcinoma, it’s a rare event. This makes sebaceous carcinoma of the breast a special case.
Histological Characteristics and Visual Markers
Diagnosing sebaceous carcinoma involves looking at specific features. Doctors look for lipid-laden cells and certain patterns. They also check for sebaceous cells with vacuolated cytoplasm.
- Presence of sebaceous cells with vacuolated cytoplasm
- Characteristic architectural patterns
- Lipid-laden cells
These signs are found through detailed exams and tests. Immunohistochemical staining helps tell it apart from other breast tumors.
Differential Diagnosis from Other Breast Neoplasms
It’s important to tell sebaceous carcinoma apart from other breast cancers. This is because they can look similar.
Doctors use a mix of clinical checks, imaging, and lab tests to diagnose. They might also use advanced tests like molecular profiling to confirm the diagnosis.
Understanding sebaceous carcinoma of the breast helps doctors improve diagnosis and treatment. This is key for managing this rare condition.
Mucinous Cystadenocarcinoma: A Rare Breast Cancer Variant
Mucinous cystadenocarcinoma is a rare type of breast cancer. It is known for its unique feature of mucin production. At Liv Hospital, we have seen many types of breast cancer. Understanding rare variants is key to treating them effectively.
Mucin Production and Cystic Features
This cancer is marked by a lot of mucin production. This leads to cysts forming in the tumor. The mucin is a key diagnostic feature and affects how the tumor behaves and responds to treatment.
“The presence of mucin is a key factor in the diagnosis of mucinous cystadenocarcinoma,” experts say. “It requires a detailed pathological examination to tell it apart from other mucinous breast lesions.”
Clinical Presentation and Physical Findings
Patients with this cancer might feel a lump or see something unusual on a mammogram. The symptoms can be like those of other breast cancers. A detailed diagnostic process is needed.
- Palpable mass or abnormality on mammography
- Firm or cystic texture on clinical examination
- Possible fixation to surrounding tissues
Documented Prevalence and Case Studies
This cancer is very rare, with only a few cases documented. There’s not much data on how common it is or how it does in the long run. But, case studies have given us insights into its behavior and treatment responses.
At Liv Hospital, we focus on caring for patients with rare cancers like mucinous cystadenocarcinoma. Our team creates personalized treatment plans for each patient’s needs.
Other Extremely Rare Forms of Breast Cancer
Looking into rare breast cancer types shows a complex world. There are many uncommon cancers that need special care. These cancers are not as well-known as common ones but are just as challenging.
Secretory Carcinoma: Features and Incidence
Secretory carcinoma is very rare and has unique features. It usually has a good outlook, mainly if caught early. Getting it right is key to treating it properly.
Key Features of Secretory Carcinoma:
- Distinctive histological pattern
- Often presents in younger patients
- Generally has a favorable prognosis
Adenoid Cystic Carcinoma of the Breast
Adenoid cystic carcinoma is another rare type. It’s known for its complex look. It can be hard to tell apart from other breast issues. Getting it right is vital for the right treatment.
Diagnostic Considerations:
- Complex histological pattern
- Risk of misdiagnosis
- Importance of expert pathological review
Neuroendocrine Tumors and Rare Papillary Breast Cancer Variants
Neuroendocrine tumors in the breast are rare. They can look like other cancers or tumors. Rare papillary breast cancer types also pose challenges. A detailed diagnosis is essential for treatment.
Clinical Implications:
- Potential for diagnostic confusion
- Need for specialized diagnostic techniques
- Importance of tailored treatment plans
Rare breast cancers need a careful approach. We focus on delivering top-notch care for all patients, including those with rare cancers. Our goal is to give each patient the care they need.
Diagnostic Complexities in Rare Breast Cancers
Diagnosing rare breast cancers is tough because they look like normal tissue. This makes it hard to find them early. We need to be more aware and use special tests to help.
Similarities to Benign Breast Lesions
Rare breast cancers can look like normal tissue. This makes it hard to tell them apart from harmless growths. They might look like benign calcifications or cysts, making diagnosis tricky.
- Diagnostic Challenges: They can be mistaken for normal tissue.
- Importance of Expertise: Only experts can spot these cancers correctly.
Advanced Imaging and Detection Techniques
New imaging tools are key in finding rare breast cancers. MRI and digital tomosynthesis help spot these cancers better. They show more detail than older methods.
These tools are vital when cancers show up differently. For example, MRI can find cancers that mammograms or ultrasound miss.
- They help find cancers more accurately.
- They show how big the cancer is and where it is.
The Critical Role of Expert Pathological Review
Getting a cancer diagnosed right is very important. Pathologists with special training can spot rare cancers. They look at the cancer’s shape, how it reacts to tests, and its genes.
They check the cancer’s look, how it reacts to tests, and its genes. This helps tell rare cancers apart from common ones and harmless growths.
Working together, doctors, radiologists, and pathologists can improve how well we diagnose and treat cancer.
Genetic Profiles and Molecular Characteristics
Understanding rare breast cancers’ genetic and molecular makeup is key to finding new treatments. We’re starting to uncover the unique genetic traits that set these cancers apart from others.
Common Genetic Mutations in Rare Breast Cancers
Rare breast cancers often have unique genetic changes that affect how they grow and respond to treatment. Some subtypes have specific mutations that could be targets for new therapies.
Table: Common Genetic Mutations in Rare Breast Cancer Subtypes
|
Rare Breast Cancer Subtype |
Common Genetic Mutation |
Potential Therapeutic Target |
|---|---|---|
|
Lipid-Rich Carcinoma |
PIK3CA mutation |
PI3K inhibitors |
|
Oncocytic Carcinoma |
Mitochondrial DNA mutations |
Mitochondrial-targeting therapies |
|
Secretory Carcinoma |
ETV6-NTRK3 fusion |
TRK inhibitors |
The Evolution of Molecular Testing Approaches
New molecular testing methods have greatly improved our ability to understand rare breast cancers. Next-generation sequencing (NGS) allows for detailed genetic profiles, helping find new treatment targets.
As testing gets better, we’re moving towards more personalized treatments for rare breast cancers. This means treatments can be tailored to each patient’s needs.
Implications for Targeted Therapy Development
Finding specific genetic mutations in rare breast cancers is a big step forward for targeted treatments. Knowing the genetic causes of these cancers helps us create more effective treatments.
For example, PIK3CA mutations in some cancers suggest PI3K inhibitors could be a good treatment. Researchers are working hard to explore these targeted treatments, giving hope to patients with rare cancers.
Tailored Treatment Approaches for Rare Breast Cancer Types
Rare breast cancers are a big challenge in cancer treatment. They need special treatment plans because of their unique traits. These plans often differ from the usual treatments for common breast cancers.
Dealing with rare breast cancers shows the importance of a multidisciplinary approach. This means doctors, surgeons, pathologists, radiologists, and geneticists working together. They create the best treatment plan for each patient.
Surgical Management as Primary Intervention
Surgery is often the first step in treating rare breast cancers. It aims to remove the tumor completely. The choice of surgery depends on the tumor’s size, location, and type.
“The role of surgery in treating rare breast cancers cannot be overstated,” experts say. “It’s often the first treatment and can greatly improve patient outcomes.”
Limited Role of Radiation Therapy in Rare Subtypes
Radiation therapy might be used for some rare breast cancer types after surgery. It helps kill any cancer cells left behind. But, it’s not always used because of the cancer’s unique traits and possible side effects.
Choosing to use radiation therapy depends on the patient’s cancer and health. We must think about the benefits and risks for each person.
Chemotherapy Considerations and Limitations
Chemotherapy is used for rare breast cancers, but it works differently for each type. The decision to use it depends on the cancer’s genetic makeup and the patient’s health. We consider the good and bad effects of chemotherapy for each patient.
- Looking at the cancer’s genetic profile to see how well chemotherapy works
- Thinking about the patient’s health and if they can handle chemotherapy
- Exploring other treatments if chemotherapy doesn’t seem right
Emerging Targeted and Personalized Therapies
New genetic and molecular tests have led to targeted therapies for rare breast cancers. These therapies are made just for the patient’s cancer. They offer hope for better treatments with fewer side effects.
As research grows, we’re moving towards more personalized treatments. We use the latest genetic and molecular tests to make therapy fit each patient’s needs.
Prognosis Factors and Survival Outcomes
Rare breast cancers are tough to predict and treat. At Liv Hospital, we focus on these cancers. We know how important it is to understand them well.
Prognostic Indicators Specific to Rare Subtypes
Prognosis for rare breast cancers is different from common ones. Size, grade, and genetic mutations matter a lot. For example, low-grade adenosquamous carcinoma (LGASC) often has PIK3CA mutations, which guide treatment.
Looking at the cancer’s cells also helps predict how it will behave. High-grade tumors or those with certain features might have a different outlook than others.
Comparative Survival Rates Among Rare Breast Cancers
Survival rates vary among rare breast cancers. Some, like mucinous cystadenocarcinoma, might do better if caught early. Others might grow faster, needing stronger treatments.
At Liv Hospital, we use advanced stats and global studies to give accurate survival rates to our patients.
Long-term Monitoring Protocols and Considerations
Watching over patients with rare breast cancers is key. Their cancers can act differently, so regular check-ups are vital. Our team at Liv Hospital creates custom plans for each patient, catching problems early.
Research keeps improving our understanding of these cancers. This helps us make treatments that fit each patient’s needs, boosting their chances of success.
Specialized Care Centers and Advanced Treatment Protocols
At Liv Hospital, we’re proud to offer top-notch care for rare breast cancers. Our goal is to use the latest medical advancements. This way, our patients get the best and most innovative treatments.
Liv Hospital’s Approach to Rare Breast Cancer Management
Liv Hospital tackles rare breast cancers in a detailed way. We use advanced diagnostic tools and personalized treatment plans. These plans are made just for each patient’s cancer.
Our multidisciplinary team comprises experts including oncologists and surgeons. They work together to create the best treatment plans. These plans are based on the latest research and guidelines.
International Academic Protocols and Standards
We follow international academic protocols and standards for rare breast cancers. Our methods are always updated with the latest global research. This ensures our patients get the most effective treatments.
- Participation in global clinical trials to access innovative treatments
- Collaboration with international oncology networks to share best practices
- Continuous education and training for our medical staff on the latest treatment protocols
Benefits of Multidisciplinary Care Teams
The multidisciplinary care team at Liv Hospital has many benefits. It brings together experts from different fields. This gives a full understanding of each patient’s condition.
This teamwork makes treatments more effective. It also improves patient outcomes and quality of life. Our team is dedicated to providing compassionate and supportive care every step of the way.
Conclusion: The Future of Rare Breast Cancer Research and Care
Exploring rare types of breast cancer shows us the need for ongoing research and specialized care. We’ve seen how complex and challenging these cancers can be to diagnose and treat.
Research is key to finding new treatments and understanding these cancers better. We need to keep supporting studies that focus on rare breast cancers. This will lead to better ways to diagnose and treat them.
The future of care for rare breast cancers depends on teamwork. Experts from different fields must work together to support patients. Places like Liv Hospital are leading the way with top-notch healthcare and specialized care centers.
It’s vital to keep rare breast cancer research and care a priority. This ensures patients get the best care possible. By doing this, we can make a big difference in the lives of those with these rare and complex cancers.
FAQs
What are the rarest types of breast cancer?
Some rare breast cancers include Low Grade Adenosquamous Carcinoma (LGASC), Lipid-rich carcinoma, and Oncocytic carcinoma. Also, Sebaceous carcinoma and Mucinous cystadenocarcinoma are very rare. These types are hard to diagnose.
How common is breast cancer globally?
Breast cancer is very common worldwide, with millions diagnosed each year. But, rare types make up a small part of these cases.
What are the characteristics of rare breast tumors?
Rare breast tumors have unique features. For example, LGASC has special histological features and often has PIK3CA mutations.
How are rare breast cancers diagnosed?
Diagnosing rare breast cancers is tough because they look like benign lesions. Advanced imaging and expert pathologists are key to correct diagnosis.
What are the treatment options for rare breast cancer types?
Treatments for rare breast cancers are tailored to each cancer’s unique traits. Options include surgery, radiation, and new targeted therapies.
What is the prognosis for rare breast cancers?
The outlook for rare breast cancers depends on the type, stage, and other factors. Knowing specific prognostic indicators and monitoring long-term is vital.
How does Liv Hospital approach the management of rare breast cancers?
Liv Hospital uses international standards to manage rare breast cancers. Their teams offer full support and treatment for these unique cancers.
Are there any genetic mutations associated with rare breast cancers?
Yes, some genetic mutations are linked to rare breast cancers. For instance, PIK3CA mutations are common in LGASC. Knowing these genetic profiles aids in creating targeted treatments.
What is the role of molecular testing in rare breast cancers?
Molecular testing is key in identifying rare breast cancers’ genetic traits. This info helps in making personalized treatment plans and targeted therapies.
Can rare breast cancers be treated with targeted therapies?
Yes, new targeted therapies hold promise for treating rare breast cancers. Understanding their genetic and molecular traits is essential for effective treatments
References
- Jenkins, S., Kachur, M. E., Rechache, K., Wells, J. M., & Lipkowitz, S. (2021, March 23). Rare breast cancer subtypes. Current Oncology Reports, 23(5), Article 54. https://doi.org/10.1007/s11912-021-01048-4 PubMed